MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Fulgent Genetics Cash Conversion Cycle 2011-2026 | FLGT
Annual Cash Conversion Cycle Fulgent Genetics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.4 | 27.6 | 24.9 | 19.6 | 25.4 | 47 | 72.6 | 4 | -40.8 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 72.6 | -40.8 | 24.7 |
Quarterly Cash Conversion Cycle Fulgent Genetics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.8 | 47.2 | 50.2 | - | 32.2 | 29.3 | 35.4 | - | 8.29 | 11.5 | 22.9 | - | 33.9 | 40.3 | 16.7 | 13.8 | 12.4 | 67.5 | 23.8 | 10.2 | 72.9 | 659 | 805 | 31.6 | 20.7 | 31.1 | 61.7 | 52.4 | 50.6 | 53.4 | 41.6 | 10.5 | -2.89 | -22.7 | -47 | -67 | -37.9 | -78 | -21.4 | 56.1 | 17.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 805 | -78 | 57.6 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Anixa Biosciences
ANIX
|
275 | $ 3.11 | -2.51 % | $ 101 K |  USA |
 |
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
-38.7 | - | -6.19 % | $ 10.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
149 | $ 30.5 | -4.72 % | $ 328 M |  China |
 |
BioNano Genomics
BNGO
|
225 | $ 1.45 | -3.67 % | $ 1.84 M | USA |
 |
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | USA |
 |
Co-Diagnostics
CODX
|
299 | - | - | $ 79.8 M | USA |
 |
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
45.9 | $ 40.78 | 1.92 % | $ 1.13 B | USA |
 |
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
133 | $ 70.44 | 1.29 % | $ 27.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
76.4 | $ 20.08 | 0.35 % | $ 1.08 B | USA |
 |
Danaher Corporation
DHR
|
83.5 | $ 234.95 | -0.44 % | $ 172 B | USA |
 |
Guardant Health
GH
|
49.1 | $ 113.62 | 1.32 % | $ 13.9 B | USA |
 |
DarioHealth Corp.
DRIO
|
207 | $ 12.48 | 0.28 % | $ 354 M |  Israel |
 |
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | USA |
 |
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | USA |
 |
Exact Sciences Corporation
EXAS
|
130 | $ 102.21 | -0.22 % | $ 18.9 B | USA |
 |
Illumina
ILMN
|
142 | $ 147.36 | 4.03 % | $ 23.4 B | USA |
 |
IQVIA Holdings
IQV
|
78 | $ 234.18 | -1.47 % | $ 42.5 B | USA |
 |
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B |  Niderland |
 |
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | USA |
 |
Lantheus Holdings
LNTH
|
90.9 | $ 66.02 | 2.75 % | $ 4.57 B | USA |
 |
Charles River Laboratories International
CRL
|
67.7 | $ 219.04 | -0.3 % | $ 11.3 B | USA |
 |
Medpace Holdings
MEDP
|
51.5 | $ 602.32 | -1.41 % | $ 18.6 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
38.6 | $ 188.87 | -0.33 % | $ 21 B | USA |
|
Biodesix
BDSX
|
41.7 | $ 8.85 | 12.25 % | $ 1.15 B | USA |
 |
Mettler-Toledo International
MTD
|
63.7 | $ 1 409.56 | -3.5 % | $ 29.9 B |  Schweiz |
 |
Laboratory Corporation of America Holdings
LH
|
39.8 | $ 272.02 | 0.42 % | $ 22.8 B | USA |
 |
ICON Public Limited Company
ICLR
|
62 | $ 176.57 | -3.31 % | $ 14.6 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
108 | $ 688.67 | -3.73 % | $ 56.8 B | USA |
 |
Myriad Genetics
MYGN
|
45.1 | $ 5.65 | -4.56 % | $ 512 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-1.24 K | $ 4.67 | -2.3 % | $ 2.51 M | USA |
 |
Neogen Corporation
NEOG
|
150 | $ 9.28 | 0.27 % | $ 2.01 B | USA |
 |
Agilent Technologies
A
|
111 | $ 135.52 | -2.95 % | $ 41.2 B | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K | Israel |
 |
Biomerica
BMRA
|
172 | $ 2.69 | 4.67 % | $ 6.18 M | USA |
 |
Bioventus
BVS
|
208 | $ 7.69 | -3.03 % | $ 482 M | USA |